Pushkal Garg Sells 1,561 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,561 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the completion of the sale, the chief marketing officer now owns 13,537 shares of the company’s stock, valued at $3,454,236.29. The trade was a 10.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, February 18th, Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.67, for a total value of $389,585.16.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $250.51 on Thursday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock’s fifty day moving average price is $253.89 and its 200 day moving average price is $263.20. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a market cap of $32.43 billion, a price-to-earnings ratio of -115.44 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ALNY. Creative Planning boosted its holdings in Alnylam Pharmaceuticals by 24.6% in the third quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock valued at $2,754,000 after purchasing an additional 1,978 shares during the last quarter. Bleakley Financial Group LLC boosted its holdings in Alnylam Pharmaceuticals by 24.7% in the third quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company’s stock valued at $609,000 after purchasing an additional 439 shares during the last quarter. Blue Trust Inc. boosted its holdings in Alnylam Pharmaceuticals by 431.0% in the third quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 375 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 62.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 161 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Alnylam Pharmaceuticals by 34.1% in the third quarter. Signaturefd LLC now owns 1,854 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 471 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of research reports. Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Scotiabank reduced their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $299.48.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.